Protein therapeutics, commonly known as monoclonal antibodies or mAbs, have emerged as the most marketed biologic drug within pharmaceutical companies.
Organic synthesis transformed the biopharmaceuticals industry by allowing companies to produce any molecule to deploy in nearly all therapeutic areas.
Dr. Dapremont on Chiral SMB in Pharma
Chiral Screening & Method Development Guide
Nitrosamine Impurities in BP Medications
Core-Shell Technology Enhances USP Isocratic Methods
SEC Method Optimization using the Ph. Eur. for Insulin Fibrils
6 Reasons to CHOOSE Luna® Omega Instead of ACQUITY® BEH
Inhalers & Parkinson's: Emerging Research
Chiral Chromatography in Pharma
USP Chapter 621: Overview & Key Points
Understanding Chirality: Key Concepts
